Literature DB >> 10371167

Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.

P R Harrigan1, M Whaley, J S Montaner.   

Abstract

OBJECTIVE: To determine the rate of plasma HIV-1 RNA rebound in patients stopping highly active antiretroviral therapy (HAART) after achieving undetectable viral load.
DESIGN: Sequential plasma HIV RNA levels were measured in six patients during the 21 days following withdrawal from HAART.
METHODS: Plasma samples were obtained from six patients who chose to withdraw from HAART because of lipodystrophy, narcotic overdose, insomnia and/or high blood pressure. Longitudinal plasma viral load was determined in triplicate upon stopping therapy.
RESULTS: All patients had plasma viral loads below 50 HIV RNA copies/ml at the time of stopping therapy and had had levels below 500 copies/ml for a median of 390 days (range 39-542 days). Plasma HIV rebound upon stopping therapy was rapid (median increase 0.2 log/day; range 0.15-0.42 log/day) and initially appeared to follow first-order kinetics. Plasma HIV RNA levels returned to greater than 500 copies/ml within 6 to 15 days (median 10 days) and approached or exceeded pre-therapy levels in all patients within 21 days of stopping therapy. Extrapolating backwards to the time at which individuals stopped therapy suggested that patients had tens of thousands of total body plasma HIV RNA copies despite having 'undetectable' plasma HIV RNA.
CONCLUSIONS: HIV RNA in plasma rebounds within days of stopping antiretroviral therapy. A considerable burden of total body plasma HIV RNA likely remains even during effective HAART therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371167     DOI: 10.1097/00002030-199905280-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  71 in total

1.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

3.  An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro.

Authors:  C McCoig; G Van Dyke; C S Chou; L J Picker; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

Authors:  Jose A Muñoz-Moreno; Carmina R Fumaz; Anna Prats; Maria J Ferrer; Eugènia Negredo; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Maite Garolera; Bonaventura Clotet
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

5.  Systems Approach to targeted and long-acting HIV/AIDS therapy.

Authors:  Rodney J Y Ho; Jesse Yu; Bowen Li; John C Kraft; Jennifer P Freeling; Josefin Koehn; Jingwei Shao
Journal:  Drug Deliv Transl Res       Date:  2015-12       Impact factor: 4.617

6.  Antiapoptotic Clone 11-Derived Peptides Induce In Vitro Death of CD4+ T Cells Susceptible to HIV-1 Infection.

Authors:  Anastassia Mikhailova; José Carlos Valle-Casuso; Annie David; Valérie Monceaux; Stevenn Volant; Caroline Passaes; Amal Elfidha; Michaela Müller-Trutwin; Jean-Luc Poyet; Asier Sáez-Cirión
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

7.  HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.

Authors:  Gideon Goldstein; Eve Damiano; Mardik Donikyan; Malika Pasha; Erik Beckwith; John Chicca
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

8.  HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.

Authors:  Joshua A Horwitz; Ariel Halper-Stromberg; Hugo Mouquet; Alexander D Gitlin; Anna Tretiakova; Thomas R Eisenreich; Marine Malbec; Sophia Gravemann; Eva Billerbeck; Marcus Dorner; Hildegard Büning; Olivier Schwartz; Elena Knops; Rolf Kaiser; Michael S Seaman; James M Wilson; Charles M Rice; Alexander Ploss; Pamela J Bjorkman; Florian Klein; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

9.  CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy.

Authors:  M Scott Killian; Jeremy Roop; Sharon Ng; Frederick M Hecht; Jay A Levy
Journal:  J Clin Immunol       Date:  2009-02-03       Impact factor: 8.317

10.  A case of multiorgan failure following interruption of antiretroviral treatment.

Authors:  M Crespo; J C Paradiñeiro; E Ribera; I Ruiz; V Falcó; J Lopez-Quiñones; I Ocaña; A Pahissa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.